Format

Send to

Choose Destination
Oncogene. 2015 Jan 2;34(1):1-14. doi: 10.1038/onc.2013.570. Epub 2014 Jan 20.

Alternative splicing in cancer: implications for biology and therapy.

Author information

1
1] Biomedical Sciences Graduate Program, University of California, San Francisco, CA, USA [2] Department of Neurology, University of California, San Francisco, CA, USA.
2
1] Department of Neurology, University of California, San Francisco, CA, USA [2] Department of Neurological Surgery and Pediatrics, University of California, San Francisco, CA, USA.

Abstract

Alternative splicing has critical roles in normal development and can promote growth and survival in cancer. Aberrant splicing, the production of noncanonical and cancer-specific mRNA transcripts, can lead to loss-of-function in tumor suppressors or activation of oncogenes and cancer pathways. Emerging data suggest that aberrant splicing products and loss of canonically spliced variants correlate with stage and progression in malignancy. Here, we review the splicing landscape of TP53, BARD1 and AR to illuminate roles for alternative splicing in cancer. We also examine the intersection between alternative splicing pathways and novel therapeutic approaches.

PMID:
24441040
DOI:
10.1038/onc.2013.570
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center